Group 1: Investor Relations Activities - The company participated in the 2025 online collective reception day for investors in Hubei on June 12, 2025 [3][4] - The event was conducted remotely via the "Panorama Roadshow" website [4] Group 2: Key Issues Addressed - The company is expanding its business into the Huang-Huai-Hai region with multiple new varieties entering the approval stage, aiming to enhance market competitiveness [6] - In the Northeast region, the company is addressing ear rot disease with two main varieties, JN 198 and HSD 568, showing significant disease resistance [6] - Strategic partnerships have been established with research institutions to enhance R&D capabilities in the Northeast [6] Group 3: M&A Plans - The company is considering M&A plans based on industry developments and its own strategic goals, with timely disclosures to be made as required [6]
DR康农种(837403) - 投资者关系活动记录表